Microparticle-Based SARS-CoV-2 Neutralizing Antibody Assay
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays for detecting SARS-CoV-2 neutralizing antibodies are either labor-intensive, time-consuming, or require significant safety precautions, making them unsuitable for rapid and reliable detection.
Innovation Solution
A method using identifiably labelled microparticles conjugated to SARS-CoV-2 proteins and a detectably labelled SARS-CoV-2 S protein receptor, which competes with neutralizing antibodies in a test sample to detect their presence or amount, allowing for rapid and sensitive neutralizing antibody detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If cell-based assays are used to detect neutralizing antibodies, then measurement precision and biological relevance are improved, but device complexity, safety requirements, and turnaround time worsen
Solution Approach 1:
The patent uses microparticles conjugated with SARS-CoV-2 proteins as simplified copies or models of the actual virus, allowing neutralizing antibody detection without requiring live viral particles. This copying approach maintains detection accuracy while eliminating the complexity and safety issues of cell-based assays
Solution Approach 2:
The patent extracts only the essential functional components (SARS-CoV-2 proteins that bind to ACE2) from the complete viral system, using these isolated proteins conjugated to microparticles to detect neutralizing antibodies. This extraction eliminates unnecessary complexity while preserving the core detection function
2Measurement precision
If cell-based assays with live virus are used, then measurement precision is improved, but safety requirements and turnaround time worsen
Solution Approach 1:
The patent replaces hazardous live virus particles with non-infectious microparticle copies displaying SARS-CoV-2 proteins, eliminating safety risks while maintaining the ability to detect neutralizing antibodies through competitive binding
Solution Approach 2:
The patent converts the potentially harmful live virus into a beneficial safe alternative by using recombinant proteins displayed on microparticles, which retain the specific binding properties needed for detection but eliminate infectious risks
3Ease of operation
If ELISA-based direct binding assays are used, then ease of operation is improved, but measurement precision and detection scope worsen
Solution Approach 1:
The patent introduces microparticles as intermediaries that enhance the ELISA-based approach by providing a suspended platform for protein display, improving antibody-microparticle interaction efficiency and enabling more accurate detection of neutralizing activity through competitive binding assays
4Measurement precision
If cell-based assays are used, then measurement precision is improved, but turnaround time worsens
Solution Approach 1:
The patent uses pre-prepared microparticle copies with conjugated proteins that can be immediately used for detection, eliminating the time-consuming cell culture and virus propagation steps required by cell-based assays while maintaining detection accuracy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a fast, reliable, and sensitive detection of SARS-CoV-2 neutralizing antibodies, correlating with cell-based assays and requiring minimal safety precautions, enabling frequent and less invasive sample collection.
Implementation Method 1
a detectably labelled SARS-CoV-2 S protein receptor or a fragment thereof, which competes with neutralizing antibodies in a test sample to detect their presence or amount
Implementation Method 2
combining at least two types of identifiably labelled microparticles conjugated to at least two different SARS-CoV-2 proteins or a fragment thereof with a detectably labelled SARS-CoV-2 S protein receptor or a fragment thereof, and a test sample
Data Source
AI summary
The present disclosure relates generally to compositions and methods for assaying antibodies. More specifically, the disclosure relates to assays that detect antibodies that have neutralizing activity against SARS-CoV-2.